CA1030871A - Compose pharmaceutique - Google Patents
Compose pharmaceutiqueInfo
- Publication number
- CA1030871A CA1030871A CA204,068A CA204068A CA1030871A CA 1030871 A CA1030871 A CA 1030871A CA 204068 A CA204068 A CA 204068A CA 1030871 A CA1030871 A CA 1030871A
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Polyethers (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB32071/73A GB1479268A (en) | 1973-07-05 | 1973-07-05 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1030871A true CA1030871A (fr) | 1978-05-09 |
Family
ID=10332744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA204,068A Expired CA1030871A (fr) | 1973-07-05 | 1974-07-04 | Compose pharmaceutique |
Country Status (13)
Country | Link |
---|---|
US (1) | US4055635A (fr) |
JP (1) | JPS5031019A (fr) |
AU (1) | AU7067574A (fr) |
BE (1) | BE817126A (fr) |
CA (1) | CA1030871A (fr) |
DE (1) | DE2432518A1 (fr) |
ES (1) | ES428053A1 (fr) |
FR (1) | FR2235699B1 (fr) |
GB (1) | GB1479268A (fr) |
IE (1) | IE40434B1 (fr) |
IL (1) | IL45103A (fr) |
NL (1) | NL7408985A (fr) |
ZA (1) | ZA743934B (fr) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2615844A1 (de) * | 1976-04-10 | 1977-10-20 | Knoll Ag | Fibrinogen spaltendes enzymsystem |
US4273873A (en) * | 1977-10-25 | 1981-06-16 | Unitika Ltd. | Preparation of antithrombogenic polymeric materials |
WO1979000515A1 (fr) * | 1978-01-16 | 1979-08-09 | Univ Boston | Methode de captage cellulaire de molecules |
US4701521A (en) * | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
JPS54157816A (en) * | 1978-05-27 | 1979-12-13 | Unitika Ltd | Fixing of bioactive substance to solid surface |
IT1209419B (it) * | 1980-07-01 | 1989-07-16 | Texcontor Ets | Composti ad attivita' mucolitica non assimilabili, processo per laloro preparazione e composizioni terapeutiche che li comprendono come principio attivo. |
JPS58189122A (ja) * | 1982-04-30 | 1983-11-04 | Kaken Pharmaceut Co Ltd | 高脂血症予防治療剤 |
GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
SE8500341L (sv) * | 1985-01-24 | 1986-07-25 | Pharmacia Ab | Desinfektionssats samt sett for desinfektion |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4745180A (en) * | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US6710169B2 (en) * | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5306500A (en) * | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
JP2896580B2 (ja) * | 1989-08-25 | 1999-05-31 | チッソ株式会社 | アミロース―リゾチームハイブリッドと活性化糖およびその製造法 |
JP2975632B2 (ja) * | 1990-03-30 | 1999-11-10 | 生化学工業株式会社 | グリコサミノグリカン修飾プロテイン |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US6458762B1 (en) | 1994-03-28 | 2002-10-01 | Baxter International, Inc. | Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis |
US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US6491965B1 (en) * | 1995-11-30 | 2002-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
US6562781B1 (en) | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
US7883693B2 (en) | 1995-12-18 | 2011-02-08 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and methods of preparation of use |
US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
ATE523211T1 (de) | 1995-12-18 | 2011-09-15 | Angiodevice Internat Gmbh | Vernetzte polymerzusammensetzungen und verfahren zu deren verwendung |
US6833408B2 (en) | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
DK0942992T3 (da) | 1997-01-31 | 2007-07-02 | Genentech Inc | O-fucosyltransferase |
US20040241645A1 (en) * | 1997-01-31 | 2004-12-02 | Genentech, Inc. | O-fucosyltransferase |
KR20010085742A (ko) * | 1998-08-28 | 2001-09-07 | 추후제출 | 정밀한 길이의 폴리아미드 사슬, 그 제조방법 및 단백질결합체의 제조방법 |
US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
JP5232352B2 (ja) * | 2001-10-10 | 2013-07-10 | ノボ ノルデイスク エイ エス | ペプチドの改造および複合糖質化 |
US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7265085B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
DK2279755T3 (da) | 2001-10-10 | 2014-05-26 | Ratiopharm Gmbh | Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF) |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7297511B2 (en) * | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7439043B2 (en) * | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7226903B2 (en) * | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7473680B2 (en) * | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
DE60336555D1 (de) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
JP2006519766A (ja) * | 2002-12-30 | 2006-08-31 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 組織反応性化合物および組成物、ならびにそれらの使用法 |
EP1594459B1 (fr) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Liberation de medicaments a partir d'une composition polymere a gelification rapide |
US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
JP4674702B2 (ja) | 2003-04-09 | 2011-04-20 | バイオジェネリクス エージー | グリコペギレ−ション法およびその方法により生成されたタンパク質/ペプチド |
WO2004091499A2 (fr) * | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Formation intracellulaire de conjugues de peptides |
MXPA05011832A (es) | 2003-05-09 | 2006-02-17 | Neose Technologies Inc | Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano. |
WO2005012484A2 (fr) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Conjugues anticorps-toxines |
US20070254834A1 (en) * | 2003-11-24 | 2007-11-01 | Defrees Shawn | Glycopegylated Erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7956032B2 (en) * | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
CA2552892C (fr) | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | Glycosylation de peptides liee a o |
KR101148445B1 (ko) | 2004-04-28 | 2012-07-05 | 안지오디바이스 인터내셔널 게엠베하 | 가교된 생합성물질을 형성하기 위한 조성물 및 시스템, 및 이와 관련된 제조 및 사용 방법 |
KR20070008645A (ko) | 2004-05-04 | 2007-01-17 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 폴리펩티드의 o-연결된 단백당형 및 그들의 제조 방법 |
EP1771066A2 (fr) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1 |
EP1789437A4 (fr) * | 2004-07-30 | 2008-11-05 | Sinai School Medicine | Inhibiteurs de npc1l1 et npc1l1 et procédés d'utilisation associés |
EP1799249A2 (fr) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Interferon alpha glycopegyle |
CA2581093C (fr) | 2004-09-17 | 2014-11-18 | Angiotech Biomaterials Corporation | Composes multifonctionels pour la formation de biomateriaux reticules et leurs procedes de preparation et d'utilisation |
WO2006035057A1 (fr) * | 2004-09-29 | 2006-04-06 | Novo Nordisk Health Care Ag | Proteines modifiees |
HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖peg化顆粒球コロニー刺激因子 |
US20060246544A1 (en) * | 2005-03-30 | 2006-11-02 | Neose Technologies,Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
US20070154992A1 (en) * | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20080255026A1 (en) * | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
WO2006127910A2 (fr) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Formulations d'erythropoietine glycopegylees |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
MX2008002395A (es) * | 2005-08-19 | 2008-03-18 | Neose Technologies Inc | Factor vii y factor viia glicopegilados. |
WO2007056191A2 (fr) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Purification de sucre de nucleotide en utilisant des membranes |
CN101516388B (zh) * | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
US20080207487A1 (en) * | 2006-11-02 | 2008-08-28 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
ES2406267T3 (es) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Métodos de tratamiento usando G-CSF glicopegilado |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
UA98001C2 (uk) | 2007-08-27 | 2012-04-10 | Биодженерикс Аг | Рідка лікарська форма кон'югата полімер-g-csf |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CN108743916A (zh) | 2008-01-22 | 2018-11-06 | 阿拉伊姆药品公司 | 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物 |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
GEP201706716B (en) | 2012-04-16 | 2017-08-10 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
US20140212405A1 (en) | 2013-01-28 | 2014-07-31 | 2294719 Ontario Limited | Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions |
CN109310741A (zh) | 2016-04-29 | 2019-02-05 | 阿拉伊姆药品公司 | 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2908614A (en) * | 1954-08-10 | 1959-10-13 | Glaxo Lab Ltd | Use of dextran in freeze-drying process |
US3019171A (en) * | 1957-11-25 | 1962-01-30 | Ethicon Inc | Activated enzyme compositions |
SE337223B (fr) * | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
NL6812443A (fr) * | 1968-08-31 | 1970-03-03 | ||
US3625827A (en) * | 1968-09-27 | 1971-12-07 | Monsanto Co | Water-soluble polymer-enzyme products |
US3616229A (en) * | 1968-09-27 | 1971-10-26 | Monsanto Co | Polymer-enzyme products comprising plurality of enzymes covalently bound to polymer |
BE744162A (fr) * | 1969-01-16 | 1970-06-15 | Fuji Photo Film Co Ltd | Procede d'encapsulage |
US3576760A (en) * | 1969-06-13 | 1971-04-27 | Nat Patent Dev Corp | Water soluble entrapping |
BE758425A (fr) * | 1969-12-02 | 1971-04-16 | Baxter Laboratories Inc | Streptokinase liee chimiquement a une matrice en carbohydrate ( |
US3876501A (en) * | 1973-05-17 | 1975-04-08 | Baxter Laboratories Inc | Binding enzymes to activated water-soluble carbohydrates |
-
1973
- 1973-07-05 GB GB32071/73A patent/GB1479268A/en not_active Expired
-
1974
- 1974-06-18 IE IE1275/74A patent/IE40434B1/xx unknown
- 1974-06-19 ZA ZA00743934A patent/ZA743934B/xx unknown
- 1974-06-21 IL IL45103A patent/IL45103A/en unknown
- 1974-07-01 FR FR7422830A patent/FR2235699B1/fr not_active Expired
- 1974-07-01 AU AU70675/74A patent/AU7067574A/en not_active Expired
- 1974-07-01 BE BE146115A patent/BE817126A/fr unknown
- 1974-07-02 US US05/485,302 patent/US4055635A/en not_active Expired - Lifetime
- 1974-07-03 NL NL7408985A patent/NL7408985A/xx not_active Application Discontinuation
- 1974-07-04 CA CA204,068A patent/CA1030871A/fr not_active Expired
- 1974-07-04 DE DE2432518A patent/DE2432518A1/de not_active Withdrawn
- 1974-07-05 JP JP49077189A patent/JPS5031019A/ja active Pending
- 1974-07-08 ES ES428053A patent/ES428053A1/es not_active Expired
Also Published As
Publication number | Publication date |
---|---|
FR2235699A1 (fr) | 1975-01-31 |
ZA743934B (en) | 1975-06-25 |
JPS5031019A (fr) | 1975-03-27 |
IE40434L (en) | 1975-01-05 |
NL7408985A (nl) | 1975-01-07 |
FR2235699B1 (fr) | 1978-07-21 |
DE2432518A1 (de) | 1975-01-30 |
IL45103A0 (en) | 1974-10-22 |
AU7067574A (en) | 1976-01-08 |
ES428053A1 (es) | 1976-11-16 |
US4055635A (en) | 1977-10-25 |
IL45103A (en) | 1977-10-31 |
BE817126A (fr) | 1975-01-02 |
IE40434B1 (en) | 1979-06-06 |
GB1479268A (en) | 1977-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1030871A (fr) | Compose pharmaceutique | |
CA1026673A (fr) | Composes pharmaceutiques | |
CA1030859A (fr) | Melanges de polyolefines et d'elastomeres | |
AU472941B2 (en) | Pharmaceutical compositions | |
AU498989B2 (en) | Pharmaceutical compositions | |
ZA744373B (en) | Pharmaceutical compositions | |
AU7201374A (en) | Pharmaceutical compositions | |
ZA744488B (en) | Pharmaceutical compositions | |
ZA745756B (en) | Pharmaceutical compositions | |
CA1024892A (fr) | Preparation pharmaceutiques renfermant des derives de triazolo-isoquinoleine | |
CA1032873A (fr) | Shampooings | |
ZA742064B (en) | Pharmaceutical compositions | |
ZA747276B (en) | Pharmaceutical compositions | |
ZA746271B (en) | Pharmaceutical compositions | |
CA1011252A (en) | Dihydrocanadensolide compositions | |
AU499890B2 (en) | Oral compositions | |
ZA741050B (en) | Pharmaceutical compositions | |
AU471794B2 (en) | Iodophor-steroid pharmaceutical compositions | |
AU485568B2 (en) | Pharmaceutical compositions | |
AU494300B2 (en) | Pharmaceutical compositions | |
AU478769B2 (en) | Pharmaceutical compositions | |
AU492729B2 (en) | Pharmaceutical compositions | |
AU493221B2 (en) | Pharmaceutical compositions | |
AU480639B2 (en) | Pharmaceutical compositions containing triazolo-isoquinoline derivatives | |
AU486937B2 (en) | Shampoo compositions |